These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38762344)

  • 1. Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of Cardiology.
    Diévart F; Bruckert E; Aboyans V; Bekka S; Boccara F; Bourdon Baron Munoz B; Emmerich J; Farnier M; Gallo A; Lemesle G; Paillard F; Schiele F; Kownator S;
    Arch Cardiovasc Dis; 2024 May; 117(5):358-378. PubMed ID: 38762344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. It's never too early to beat your low-density lipoprotein cholesterol.
    Bergerot C; Angoulvant D; Lemesle G; Barone-Rochette G; Mewton N; Mach F
    Arch Cardiovasc Dis; 2021 Jan; 114(1):1-3. PubMed ID: 33509745
    [No Abstract]   [Full Text] [Related]  

  • 6. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence.
    Stauffer ME; Weisenfluh L; Morrison A
    Vasc Health Risk Manag; 2013; 9():671-80. PubMed ID: 24204156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Hollan I; Ronda N; Dessein P; Agewall S; Karpouzas G; Tamargo J; Niessner A; Savarese G; Rosano G; Kaski JC; Wassmann S; Meroni PL
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):104-114. PubMed ID: 31397840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
    Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
    Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 11. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.
    Ferrières J; Rouyer MV; Lautsch D; Ashton V; Ambegaonkar BM; Brudi P; Gitt AK;
    Arch Cardiovasc Dis; 2017 Mar; 110(3):167-178. PubMed ID: 28209375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice.
    Sinning D; Landmesser U
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):71-76. PubMed ID: 28618905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ECS guidelines 2016 - dyslipidaemias].
    Sinning D; Landmesser U
    Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.
    Millán J; Pintó X; Muñoz A; Zúñiga M; Rubiés-Prat J; Pallardo LF; Masana L; Mangas A; Hernández-Mijares A; González-Santos P; Ascaso JF; Pedro-Botet J
    Vasc Health Risk Manag; 2009; 5():757-65. PubMed ID: 19774217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.